PharmaCyte (PMCB) - סך כל נכסי החברה

A stable operating environment in the US and the humanitarian status of its developments minimize external threats for PharmaCyte Biotech (PMCB), which is led by a team of scientists strictly adhering to legal norms and cost transparency. The verified price history on the total assets chart on GURU.Markets stands at 52.27, while the business relies on the creation of biopolymer capsules for targeted therapy of oncological diseases and diabetes, thereby reducing technological risks.

For PharmaCyte Biotech (PMCB), which implements robotic automation in preclinical testing of oncology drugs, total assets determine the scale of the material base, where the trajectory of all company resources is reverse-calculated via ROA as the sum of equity and liabilities. This trend reflects the efficiency of accumulating funds to scale software robots, allowing investors to differentiate organic base growth from risky debt leverage.